Skip to main content

Table 3 Clinical features and outcome of three groups

From: Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms

Index

PMF

(n = 24)

PV

(n = 80)

ET

(n = 68)

P

Whole group

PMF vs. PV

PMF vs. ET

PV vs. ET

Age(year)

65.5(42–78)

58(21–78)

57(18–77)

0.122

   

sex

   

0.180

   

male

17

49

35

    

female

7

31

33

    

abnormal chromosome

6

5

2

< 0.001*

0.003*

0.001*

0.686

JAK2 V617Fmutation

15

73

47

< 0.001*

0.007*

0.723

0.005*

Splenomegaly

24

58

23

< 0.001*

0.003*

< 0.001*

< 0.001*

Thrombosis

2

13

12

0.550

0.511

0.342

0.821

hemorrhage

1

5

1

0.341

0.578

0.456

0.219

Leukaemia

1

0

0

0.045

0.231

0.261

/

Bone fibrosis

/

2

3

0.661

  

0.661

High LDH

24

56

39

0.001*

0.002*

< 0.001*

0.110